English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

Performance characteristics of the Abbott LCx ®  HIV RNA Quantitative Assay (LCx HIV) were established in a multicenter study comparing it with the manual (Amplicor v1.5) and automated (Cobas) ultra-sensitive Roche Amplicor™ HIV-1 Monitor v1.5, the Bayer Quantiplex™ HIV RNA 3.0 (bDNA v3.0), and the Organon NucliSens ®  HIV QT 2.0 (NucliSens). Within-run precision of LCx HIV assessed in clinical specimens was SD log 10  0.210 at ~50 copies/ml, and log 10  0.133 at ~400 copies/ml. Total precision in a reconstituted type B HIV-1 RNA panel was SD log 10  0.380 at 100 copies/ml, and SD log 10  0.180 at 1000 copies/ml. Type B HIV-1 RNA sensitivity (1 ml input) assessed at a 50%, 75% and 95% detection rate ranged from 29 to 41, 54 to 75 and 94 to 176 copies/ml, respectively. Overall specificity in HIV sero-negative individuals was 99.78%. Linear regression indicated close assay correlations and agreements for measurement of type B HIV-1 RNA. Pearson's correlations and (Log 10 LCx=aLog 10 x + b) linear regressions were 0.91 (y=0.892 Log 10 Amplicor + 0.595), 0.93 (y=0.827 Log 10 Cobas + 0.969), 0.93 (y=0.951 Log 10 bDNA + 0.550), and 0.79 (y=0.834 Log 10 nuclisens + 0.911). LCx HIV was least affected by the genetic variability of HIV-1. LCx HIV detected 99% of non-type B HIV-1 group M samples (subtypes A-G), Amplicor v1.5 detected 96%, and bDNA v3.0 detected 99%. The assays detected 10/11, 1/11 and 8/11, respectively of the HIV-1 group O samples. LCx HIV  vs.  Amplicor/bDNA Spearman's rank correlations for quantification of non-type B HIV-1 RNA were 0.76/0.84 (A), 0.93/0.93 (C), 0.73/0.99 (D), 0.86/0.98 (E), and 0.40/0.83 (group O). LCx HIV assays consistently detect and quantify type B, non-type B and group O HIV-1 RNA.

clinical chemistry and laboratory medicine

Multicenter Study of the LCx® HIV RNA Quantitative Assay –   a New Competitive Reverse Transcriptase-PCR which Targets pol Genomic Region of HIV-1 for the Measurement of Type B, Non-Type B and Group O HIV-1 RNA